<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902083</url>
  </required_header>
  <id_info>
    <org_study_id>rAd-p53-002</org_study_id>
    <nct_id>NCT00902083</nct_id>
  </id_info>
  <brief_title>rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors</brief_title>
  <acronym>rAd-p53</acronym>
  <official_title>Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Chemotherapy, or Combination With Surgery in Subjects With Advanced Oral and Maxillofacial Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen SiBiono GeneTech Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen SiBiono GeneTech Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicenter, open-label, randomized, active-controled, phase IV study of local direct
      intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , or combination
      with surgery for treatment of advanced oral and maxillofacial malignant tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives of this study is to determine the efficacy profiles of rAd-p53 intra-tumor
      injection alone, with concurrent chemotherapy, or combination with surgery for treatment of
      advanced oral and maxillofacial malignant tumors(stage III or IV) including target lesion
      complete response rate (LCR) and overall target lesion response rate (OLR), response duration
      (RD), and progress-free survival (PFS).

      The secondary objectives of this study is to investigate overall response rate (OPCR) and
      overall complete response rate (OCR), overall survival (OS), ECOG, and safety of rAd-p53
      monotherapy and combined with chemotherapy,or surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall best response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progress free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Advanced Oral and Maxillofacial Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>surgery plus p53 gene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using p53 gene therapy before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surgery alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery without pre-p53 gene therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>p53 plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p53 gene therapy with concurrent chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>p53 gene therapy alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-tumor injectio of rAd-p53 gene with no concurrent treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>p53 gene with surgery</intervention_name>
    <description>pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times</description>
    <arm_group_label>surgery plus p53 gene</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>remove tumor surgery</description>
    <arm_group_label>surgery alone</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>p53 with chemotherapy</intervention_name>
    <description>p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy</description>
    <arm_group_label>p53 plus chemotherapy</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>p53 gene therapy</intervention_name>
    <description>p53 gene treatment: 10exp12 virus particles per 3 days for 10 times</description>
    <arm_group_label>p53 gene therapy alone</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced stages of Oral and Maxillofacial malignant tumors (stage III and VI)

          2. At least one target tumor can be injected with study drug, the largest diameter
             greater than 2 cm

          3. Histologically confirmed Oral and Maxillofacial malignant tumors

          4. No prior chemotherapy, radiotherapy or biological tumor therapy in 2 weeks

          5. Age: 18-85 years old

          6. Expected to survive more 12 weeks

          7. ECOG:0-2

          8. Neutrophils≥1.5×109/L,Platelet≥ 80×109/L, Hb≥80g/L, bilitubin≤2mg/dl,ALT and AST
             ≤2×institutional upper limit of normal, Cr ≤1.5×institutional upper limit of
             normal,coagulation tests (PTT and INR) within normal range

          9. Subject provided signed informed consent

        Exclusion Criteria:

          1. Hypersensitive to study drug

          2. Tumor(s) locate very close to important blood vessels and nerves, which affect
             injection

          3. With a coagulation and bleeding disorder

          4. With uncontrolled, intercurrent illness including but limited to symptomatic
             neurological illness, symptomatic congestive heart failure, unstable angina pectoris,
             significant pulmonary disease or hypoxia, or psychiatric illness

          5. Local infection close to injection site or systemic infection

          6. Pregnant or lactating

          7. Principle investigator consider not suitable -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Longjiang Li, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>qing yu, MD</last_name>
    <phone>86-755-33065218</phone>
    <email>qingyu36@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Longjiang Li, PhD, MD</last_name>
      <phone>86-28-85503389</phone>
      <email>muzili63@163.com</email>
    </contact>
    <investigator>
      <last_name>Longjiang Li, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2009</study_first_posted>
  <last_update_submitted>April 6, 2012</last_update_submitted>
  <last_update_submitted_qc>April 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>p53 gene</keyword>
  <keyword>Oral and Maxillofacial</keyword>
  <keyword>gene therapy</keyword>
  <keyword>malignant tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

